Skip to main content

CORRECTION article

Front. Oncol., 02 December 2015
Sec. Cancer Genetics

Corrigendum: Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management

Thomas Paul Slavin*Thomas Paul Slavin*Mariana Niell-SwillerMariana Niell-SwillerIlana SolomonIlana SolomonBita NehorayBita NehorayChristina RybakChristina RybakKathleen R. BlazerKathleen R. BlazerJeffrey N. Weitzel\r\n   Jeffrey N. Weitzel
  • Division of Clinical Cancer Genetics, Department of Medical Oncology, City of Hope, Duarte, CA, USA

A corrigendum on

Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management
Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, et al. Front Oncol (2015) 5:208. doi: 10.3389/fonc.2015.00208

On page 4 of our manuscript, line 528, there is an erroneous reference for Figure 3.

“Mosaic TP53

Case 2 is a 42-year-old unaffected woman of Northern European ancestry referred for interpretation of ambiguous results from a breast focused multigene panel ordered by her referring physician due to her maternal family history of cancer (Figure 3);”

Figure 3 only pertains to the CDH1 case above (correctly referenced there). Therefore, the sentence should read:

“Case 2 is a 42-year-old unaffected woman of Northern European ancestry referred for interpretation of ambiguous results from a breast focused multigene panel ordered by her referring physician due to her maternal family history of cancer;”

We apologize for any confusion this may have caused.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: genetics, multigene panels, genetic counseling, BRCA1

Citation: Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR and Weitzel JN (2015) Corrigendum: Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front. Oncol. 5:271. doi: 10.3389/fonc.2015.00271

Received: 02 November 2015; Accepted: 20 November 2015;
Published: 02 December 2015

Edited by:

Pamela Pollock, Institute for Health and Biomedical Innovation, Australia

Reviewed by:

Nhan Le Tran, Translational Genomics Research Institute, USA
Parvin Mehdipour, Tehran University of Medical Sciences, Iran

Copyright: © 2015 Slavin, Niell-Swiller, Solomon, Nehoray, Rybak, Blazer and Weitzel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Thomas Paul Slavin, tslavin@coh.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.